Avanir Pharmaceuticals (NASDAQ: AVNR) 179% HIGHER; Announced positive top-line results from the company's Phase III clinical trial evaluating the investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE